Abstracts Archive - Page 1184 of 2425 - ACR Meeting Abstracts

Abstract Number: 2693 • 2018 ACR/ARHP Annual Meeting
What Is the Effect of Cyclophosphamide Iv Pulse Therapy in Patients with Diffuse Cutaneous Systemic Sclerosis on Skin Involvement: An Observational Study
Brigit Kersten, Nathan den Broeder, Frank van den Hoogen, Els van den Ende and Madelon Vonk, Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands
Background/Purpose: Patients with systemic sclerosis who have proximal skin involvement are classified as diffuse cutaneous systemic sclerosis (DcSSc). Patients with progressive skin involvement have worse prognosis.…
Abstract Number: 2694 • 2018 ACR/ARHP Annual Meeting
Performance of Anti-Scl-70 Antibody Testing By Multiple-Bead, Enzyme-Linked Immunosorbent Assay, and Immunodiffusion in a University Setting
Kate Homer¹, Jeffery Warren², Dmitry Karayev³, Puja P. Khanna⁴, Amber Young⁵, Vivek Nagaraja⁵, Allan L. Metzger⁶ and Dinesh Khanna⁵, ¹Department of Internal Medicine, Rheumatology Division, Scleroderma Program, University of Michigan, Ann Arbor, MI, ²Department of Pathology, University of Michigan, Ann Arbor, MI, ³RDL Reference Laboratory, Santa Monica, CA, ⁴University of Michigan, Ann Arbor, MI, ⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ⁶RDL Reference Laboratory, Los Angeles, CA
Background/Purpose: The gold standard for anti-Scl-70 antibody testing in systemic sclerosis (SSc) uses immunodiffusion (ID) techniques, but enzyme-linked immunosorbent assay (ELISA) and multi-bead technology are…
Abstract Number: 2695 • 2018 ACR/ARHP Annual Meeting
Progressive Skin Fibrosis, Internal Organ Involvement and All-Cause Mortality in an Early Diffuse Cutaneous Systemic Sclerosis United States Multicenter Registry
Kate Homer¹, Benjamin Brennan², Shervin Assassi³, Elana J. Bernstein⁴, Flavia V. Castelino⁵, Robyn T. Domsic⁶, Jessica K. Gordon⁷, Faye N. Hant⁸, Monique Hinchcliff⁹, Ami A. Shah¹⁰, Victoria Shanmugam¹¹, Virginia D. Steen¹², Veronica J. Berrocal¹³, Melanie Hemmrich¹⁴, Tracy M. Frech¹⁵ and Dinesh Khanna¹⁶, ¹Department of Internal Medicine, Rheumatology Division, Scleroderma Program, University of Michigan, Ann Arbor, MI, ²School of Public Health, University of Michigan, Ann Arbor, MI, ³University of Texas McGovern Medical School, Houston, TX, ⁴Rheumatology, Columbia University, New York, NY, ⁵Rheumatology, Harvard Medical School, Boston, MA, ⁶Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁹Rheumatology, Northwestern University, Chicago, IL, ¹⁰Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹¹Rheumatology, The George Washington University, Washington, DC, ¹²Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ¹³Div of Rheumatology, University of Michigan, Ann Arbor, MI, ¹⁴Bayer AG, Wuppertal, Germany, ¹⁵Division of Rheumatology, University of Utah, Salt Lake City, UT, ¹⁶Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI
Background/Purpose: Early diffuse cutaneous systemic sclerosis (dcSSc) carries a high morbidity and mortality, predominantly due to internal organ involvement. The purpose of this study was…
Abstract Number: 2696 • 2018 ACR/ARHP Annual Meeting
Increased Mortality in Black and Asian Patients with Systemic Sclerosis in Northern California
Melody Chung¹, Makdine Dontsi², Debbie Postlethwaite², Sumana Kesh³, Lisa Zaba⁴ and Lorinda Chung^5,6, ¹Internal Medicine Residency, Kaiser Permanente Santa Clara, Santa Clara, CA, ²Division of Research, Kaiser Permanente Northern California, Oakland, CA, ³Department of Internal Medicine, Kaiser Permanente Santa Clara, Santa Clara, CA, ⁴Department of Dermatology, Kaiser Permanente Santa Clara, Santa Clara, CA, ⁵Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁶VA Palo Alto Health Care System, Palo Alto, CA
Background/Purpose: Studies indicate that black patients with systemic sclerosis (SSc) demonstrate a distinct phenotypic profile, with more severe disease, heightened mortality, and poorer prognosis compared…
Abstract Number: 2697 • 2018 ACR/ARHP Annual Meeting
Elevated Serum Interleukin-34 Levels Are Correlated with Interstitial Lung Disease in Systemic Sclerosis
Hiraku Suga¹, Ai Kuzumi¹, Yoshihide Asano¹, Ayumi Yoshizaki¹ and Shinichi Sato², ¹Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²The University of Tokyo, Department of Dermatology, Tokyo, Japan
Background/Purpose: Interleukin (IL)-34 is a hematopoietic cytokine, which promotes survival, proliferation, and differentiation of monocytes and macrophages. We investigated serum IL-34 levels in patients with…
Abstract Number: 2698 • 2018 ACR/ARHP Annual Meeting
Renal Involvement in Mixed Connective Tissue Disease: A Single Center Experience
Eduardo Martín Nares¹, Silvia Eunice Ramírez Andrade², Luis Eduardo Morales Buenrostro², Norma Ofelia Uribe Uribe³, Laura R Cárdenas M³, Montserrat Reyes Macedo³ and Tatiana S. Rodriguez-Reyna¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Nephrology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Department of Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Kidney injury in mixed connective tissue disease (MCTD) is an uncommon manifestation. Prevalence has been reported to be <4% in some cohorts. The frequency…
Abstract Number: 2699 • 2018 ACR/ARHP Annual Meeting
Using ICD-10 Codes to Identify Patients with Systemic Sclerosis in the Electronic Health Record
Lia Jamian¹, Leslie Crofford² and April Barnado², ¹Medicine, Vanderbilt University Medical Center, Nashville, TN, ²Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Pragmatic research in rare diseases is difficult, largely limited by small sample size and single center cohort studies. The electronic health record (EHR) can…
Abstract Number: 2700 • 2018 ACR/ARHP Annual Meeting
Rescuing Standard Analyses of Immunosuppresive Rescue Therapy in Randomized Controlled Trials: Alternative Approaches in a Scleroderma Clinical Trial
Cathie Spino¹, Robert A. Parker² and Dinesh Khanna³, ¹Biostatistics, University of Michigan, Ann Arbor, MI, ²Medicine-Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI
Background/Purpose: Placebo-controlled clinical trials are the gold standard to provide the highest-quality evidence of treatment efficacy; however, in early SSc, requiring participants to take long-term…
Abstract Number: 2701 • 2018 ACR/ARHP Annual Meeting
Botulinum Toxin in the Management of Raynaud’s Phenomenon
Daniel Ennis^1,2, Zareen Ahmad³, Keshini Devakandan¹, Melanie A Anderson⁴ and Sindhu Johnson¹, ¹Toronto Scleroderma Program, Mount Sinai Hospital, Toronto Western Hospital, Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Rheumatology, University of British Columbia, Vancouver, BC, Canada, ³Toronto Scleroderma Program, Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴University Health Network Library Services, Toronto General Hospital, Toronto, ON, Canada
Background/Purpose: The objectives of this study were to evaluate the effectiveness and safety of botulinum toxin injection in Raynaud’s phenomenon. Methods: Medline and Embase databases…
Abstract Number: 2702 • 2018 ACR/ARHP Annual Meeting
Incidence, Prevalence, Mortality and Comparison of the Acr/EULAR 2013 Classification Criteria with 1980 Criteria in Physician Diagnosed Systemic Sclerosis: Results from a Population Based Cohort (1980-2016)
Avneek Singh Sandhu¹, Cynthia S. Crowson², Philippe R. Bauer³, Eric L. Matteson⁴ and Ashima Makol¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ⁴Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: Systemic Sclerosis (SSc) is a complex and heterogenous chronic inflammatory disease characterized by widespread fibrosis of the skin and visceral organs, microvascular injury and…
Abstract Number: 2703 • 2018 ACR/ARHP Annual Meeting
Delay in Initiation of Therapy Predicts Worse Outcomes in Scleroderma Renal Crisis
Aditi Patel¹, Kinjal Banerjee² and Soumya Chatterjee³, ¹Internal Medicine, Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH, ³Rheumatic and Immunologic Disease, Cleveland Clinic, Cleveland, OH
Background/Purpose: Scleroderma renal crisis (SRC) is a rare complication of patients with systemic sclerosis (SSc). ACE inhibitors (ACEI) favorably alter the natural history of this…
Abstract Number: 2704 • 2018 ACR/ARHP Annual Meeting
Pregnancy in Systemic Sclerosis (SSc): A Systematic Review and Meta-Analysis
Jelena Blagojevic¹, Khitam Abdullah AlOdhaibi², Aly M Aly³, Marco Matucci-Cerinic⁴ and Daniel E. Furst^5,6,7, ¹Department of Experimental and Clinical Medicine, University of Florence, Division of Rheumatology AOUC, Florence, Italy, ²Department of Family Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia, ³Alexandria University Faculty of Medicine, Alexandria, Egypt, ⁴Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁵University of California, Los Angeles (UCLA), Los Angeles, CA, ⁶University of Florence, Florence, Italy, ⁷University of Washington, Seattle, WA
Background/Purpose: In a systematic literature review and meta-analysis, to determine maternal and fetal outcomes in pregnant SSc women and to analyse the effect of pregnancy…
Abstract Number: 2705 • 2018 ACR/ARHP Annual Meeting
Optimized Protocol for Extracorporeal Shock Wave Therapy on Digital Ulcers in Systemic Sclerosis
Tomonori Ishii¹, Yasushi Kawaguchi², Osamu Ishikawa³, Hiromitsu Takemori⁴, Naruhiko Takasawa⁵, Hitoshi Kobayashi⁶, Yuichi Takahashi⁷, Hidekata Yasuoka⁸, Takao Kodera⁹, Osamu Takai¹⁰, Izaya Nakaya¹¹, Tomomasa Izumiyama¹², Hiroshi Fujii¹³, Yukiko Kamogawa¹³, Yuko Shirota¹³, Tsuyoshi Shirai¹³, Yoko Fujita¹⁴, shinichiro saito¹⁵, Hiroaki Shimokawa¹⁶ and Hideo Harigae¹³, ¹Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan, ²Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ³Department of Dermatology, Gunma University Graduate School of Medicine, gunma, Japan, ⁴Aomori Prefectural Central Hospital, Aomori, Japan, ⁵Department of Internal Medicine, Tohoku Medical and Pharmaceutical University Wakabayashi Hospital, Sendai, Japan, ⁶Iwate Medical University Hospital, Morioka, Japan, ⁷Ｙｕ　Ｆａｍｉｌｙ　Ｃlinic, Sendai, Japan, ⁸Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, tokyo, Japan, ⁹Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, ¹⁰Osaki Citizen Hospital, Sendai, Japan, ¹¹Department of Nephrology and Rheumatology, Iwate Prefectural Central Hospital, Morioka, Japan, ¹²Higashisendai Rheumatic Disease Clinic, Sendai, Japan, ¹³Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ¹⁴Department of Hematolgy and Rheumatolgy, Tohoku University Graduate School of Medicine, Sendai, Japan, ¹⁵IMS Meirikai Sendai General Hospital, Sendai, Japan, ¹⁶Department of Cardiovascular medicine, Tohoku University Graduate School of Medicine, Sendai, Japan
Background/Purpose: Extracorporeal shock wave therapy (ESWT) at low energy has been shown to be effective for digital ulcers in systemic sclerosis (SSc) in our study…
Abstract Number: 2706 • 2018 ACR/ARHP Annual Meeting
Discriminant Validity and Reliability of World Scleroderma Foundation (WSF) Definition of Skin Ulcers in Systemic Sclerosis
Yossra A Suliman¹, Cosimo Bruni², Sindhu Johnson³, Suzanne Kafaja⁴, Emanuela Praino⁵, Dinesh Khanna⁶, Yannick Allanore⁷, Murray Baron⁸, Jonathan Grotts⁹, Thomas Krieg¹⁰, Ariane L. Herrick¹¹, Christopher P. Denton¹², Marco Matucci-Cerinic¹³ and Daniel E. Furst¹⁴, ¹Rheumatology and Rehabilitation dept., Rheumatology and Rehabilitation dept. Assiut university hospital, Assiut Egypt, Assiut, Egypt, ²Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Firenze, Italy, ³Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁵DIM, Rheumatology Unit - D.E.T.O. - University of Bari (ITALY), Bari, Italy, ⁶Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ⁷Service de Rhumatologie A, Hôpital Cochin, Paris, France, ⁸Rheumatology, Jewish General Hospital, Montreal, QC, Canada, ⁹Biostatistics, University of California Los Angeles, Los Angeles, CA, ¹⁰Universität zu Köln, Köln, Germany, ¹¹Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, United Kingdom, ¹²UCL Division of Medicine, Royal Free Campus, London, United Kingdom, ¹³Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ¹⁴Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: To date, there is lack of a uniform definition of systemic sclerosis related skin ulcer (SSc-skin ulcer) for use in clinical trials. Our group…
Abstract Number: 2707 • 2018 ACR/ARHP Annual Meeting
Scleroderma Renal Crisis: The Association of High-Dose Steroids and Poor Outcome
Nilasha Ghosh¹, Xuan Cai² and Cybele Ghossein³, ¹Internal Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Nephrology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Scleroderma renal crisis (SRC) is the most acute and life-threatening complication of scleroderma characterized by sudden increase in blood pressure and worsening kidney function.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].